Pharmaceuticals

Automated Liquid Handling Systems Industry Poised for Rapid Expansion, Projected to Hit $4.16 Billion by 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Are the Forecasted Growth Rate and Market Size of the Automated Liquid Handling Systems Market?#_x000D_

In recent times, the market size for medulloblastoma drugs has seen a significant expansion. There will be a growth from $2.8 billion in 2024 to $3.03 billion in 2025 with an 8.3% compound annual growth rate (CAGR). The growth during the past period can be ascribed to factors such as a heightened incidences of brain tumors in children, a surge in investments towards oncology-centric biotech firms, advancements in brain tumor diagnostic techniques, increased knowledge about child-related cancers and a better understanding of genetics and tumor biology._x000D_

_x000D_

In the coming years, it is forecasted that the market size for medulloblastoma drugs will experience significant growth, with projections estimating it to reach “$4.16 billion in 2029 with a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this spike during the forecast period include the escalation of clinical trials related to medulloblastoma, advancements in precision medicine and customized treatment plans, increasing demand for combination treatments in cancer care, heightened attention on rare and orphan disease drug development, and a conducive regulatory climate for approving new drugs. Key trends for the forecast period feature the proliferation of combination therapies, the integration of artificial intelligence in pharmaceutical research, progressive strides in liquid biopsy for identifying brain tumors, enhancement in gene therapy for targeted tumor treatments, and partnerships between pharmaceutical corporations and research entities._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=20874&type=smp_x000D_

_x000D_

#Which Factor Is Shaping The Future Of The Automated Liquid Handling Systems Market?#_x000D_

The rise in chronic illnesses is anticipated to boost the automated liquid handling systems market’s expansion. Chronic diseases are enduring conditions that can be controlled but usually not fully cured. The increase in these diseases can be attributed to the higher intake of processed foods, sustained periods of inactivity, and low levels of physical exercise. Automated liquid handling systems, with their improved accuracy, reproducibility, and throughput compared to manual pipetting, are vital within the pharmaceutical and biotech sectors. For example, an August 2022 report by the American College of Cardiology, a non-profit medical association based in the US, reveals projections of increases in all four primary cardiovascular risk factors from 2025 to 2060. Diabetes is predicted to see the highest percentage increase, with a rise of 39.3% to 55 million people, followed by dyslipidemia (increasing 27.6% to 126 million), hypertension (surging 25.1% to 162 million) and obesity (rising 18.3% to 126 million). Additionally, considerable surges in cardiovascular disease rates are forecasted for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), while ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) are not far behind. This rising incidence of chronic disease is therefore fueling the automated liquid handling systems market’s growth._x000D_

_x000D_

The medulloblastoma drug market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Dianhydrogalactitol, Investigational Medicinal Product 5471, Ipilimumab, Indoximod, Other Types_x000D_

2) By Product: Chemotherapy Drugs, Targeted Therapy Drugs, Radiation Therapy Drugs_x000D_

3) By Route Of Administration: Intravenous, Oral, Intrathecal_x000D_

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy_x000D_

5) By End-Users: Hospitals, Homecare, Speciality Centres, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Dianhydrogalactitol: Dianhydrogalactitol Oral Formulations, Dianhydrogalactitol Intravenous Formulations _x000D_

2) By Investigational Medicinal Product 5471: Oral Investigational Medicinal Product 5471, Intravenous Investigational Medicinal Product 5471 _x000D_

3) By Ipilimumab: Ipilimumab Monotherapy, Ipilimumab Combination Therapy _x000D_

4) By Indoximod: Indoximod Oral Formulations, Indoximod Combination Therapy _x000D_

5) By Other Types: Temozolomide, Lomustine, Cyclophosphamide, Targeted Therapy Drugs _x000D_

_x000D_

#What Upcoming Trends Are Expected To Impact The Automated Liquid Handling Systems Market Globally?#_x000D_

Key firms in the medulloblastoma drug market are striving to develop more sophisticated medications, such as chemotherapy drugs, to secure a competitive advantage. The chemotherapy drug temozolomide is frequently utilized to treat certain brain cancers such as glioblastoma, and in some scenarios, medulloblastoma, by damaging the DNA of cancer cells and preventing their growth and division. For example, Accord Healthcare, Inc., a generic pharmaceutical firm based in the United States, released a generic variant of Carmustine in August 2022. Carmustine is a chemotherapy drug that is especially important in the treatment of medulloblastoma, a common type of brain cancer in children. The new preparation comes in two different strengths: 50 mg and a larger 300 mg vial, which simplifies treatment by reducing the necessity for multiple smaller vials. Carmustine, an alkylating agent, impedes the growth of cancer cells and has been approved by the FDA as an individual treatment or in combination with other treatments for various cancers, including medulloblastoma, glioblastoma, and certain blood malignancies._x000D_

_x000D_

#Which Companies Hold The Largest Market Share In The Automated Liquid Handling Systems Sector?#_x000D_

Major companies operating in the medulloblastoma drug market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Biocon Limited, Teva Pharmaceutical Industries Ltd, Eisai Co. Ltd., Ipsen S.A., Daiichi Sankyo Co. Ltd., Lumos Pharma Inc., Biodexa Pharmaceuticals plc, Eagle Biosciences Inc., Cayman Chemical Company, Biosynth Carbosynth AG, Curtana Pharmaceuticals Inc., VBI Vaccines Inc. _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/medulloblastoma-drug-global-market-report_x000D_

_x000D_

#How Does Regional Performance Compare Across The Automated Liquid Handling Systems Industry?#_x000D_

North America was the largest region in the medulloblastoma drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medulloblastoma drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=20874&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_